Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer

被引:14
作者
Witteveen, PO
van Groenestijn, MAC
Blijham, GH
Schrijvers, AJP
机构
[1] Univ Utrecht Hosp, Dept Internal Med, Sect Med Oncol, Utrecht, Netherlands
[2] Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands
关键词
cost; end-stage cancer; home care technology; palliative care; parenteral fluids and analgesics;
D O I
10.1023/A:1008364401890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. In 1992 a home care technology project was started in which infusion therapy in the home settings was made available for patients with end-stage cancer. Beside aspects of feasibility and quality of life the resource utilization and costs of this transition was studied. Patients and methods: We conducted a cost evaluation study, to determine the actual cost of managing patients with endstage cancer who require parenteral administration of fluid or analgesics in the home setting. A total of 128 patients were prospectively followed, with a detailed analysis of some aspects in a sample of 24 patients. Results: The cost for each patient was found to be between $250.00 and $300.00 per day, half of which are for hospital charges, even with this active home care technology program. One-third of the costs can be attributed to primary health care activities, in particular those of the district nurses. A hypothetical control group (n = 25) was constructed based on current practice and chart review. Patients in this group would have cost around $750.00 per day. With a median treatment period of 16 days this means a saving of $8000.00 per patient. Conclusion: Our data suggest that significant savings can be obtained by implementing programs transferring palliative care technology to the home setting.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 12 条
[1]  
BOUDEWIJN JWT, 1993, THUISZORG BERIJFS EC
[2]   A COST-MINIMIZATION STUDY OF CANCER-PATIENTS REQUIRING A NARCOTIC INFUSION IN HOSPITAL AND AT HOME [J].
FERRIS, FD ;
WODINSKY, HB ;
KERR, IG ;
SONE, M ;
HUME, S ;
COONS, C .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1991, 44 (03) :313-327
[3]   Evolving costs of long-term left ventricular assist device implantation [J].
Gelijns, AC ;
Richards, AF ;
Williams, DL ;
Oz, MC ;
Oliveira, J ;
Moskowitz, AJ .
ANNALS OF THORACIC SURGERY, 1997, 64 (05) :1312-1319
[4]   COST-EFFECTIVENESS OF PALLIATIVE CHEMOTHERAPY IN ADVANCED GASTROINTESTINAL CANCER [J].
GLIMELIUS, B ;
HOFFMAN, K ;
GRAF, W ;
HAGLUND, U ;
NYREN, O ;
PAHLMAN, L ;
SJODEN, PO .
ANNALS OF ONCOLOGY, 1995, 6 (03) :267-274
[5]   COST-EFFECTIVENESS OF CANCER-CHEMOTHERAPY - AN ECONOMIC-EVALUATION OF A RANDOMIZED TRIAL IN SMALL-CELL LUNG-CANCER [J].
GOODWIN, PJ ;
FELD, R ;
EVANS, WK ;
PATER, J .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1537-1547
[6]   EFFICACY AND COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN WOMEN WITH NODE-NEGATIVE BREAST-CANCER - A DECISION-ANALYSIS MODEL [J].
HILLNER, BE ;
SMITH, TJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (03) :160-168
[7]   EFFICACY AND COST-EFFECTIVENESS OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN METASTATIC BREAST-CANCER - ESTIMATES USING DECISION-ANALYSIS WHILE AWAITING CLINICAL-TRIAL RESULTS [J].
HILLNER, BE ;
SMITH, TJ ;
DESCH, CE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (15) :2055-2061
[8]   THE USAGE AND COSTS OF HEALTH-SERVICES FOR HIV-INFECTION IN AUSTRALIA [J].
HURLEY, SF ;
KALDOR, JM ;
CARLIN, JB ;
GARDINER, S ;
EVANS, DB ;
CHONDROS, P ;
HOY, J ;
SPELMAN, D ;
SPICER, WJ ;
WRAIGHT, H ;
MEESE, P .
AIDS, 1995, 9 (07) :777-785
[9]   COUNTING THE COSTS OF CHEMOTHERAPY IN A NATIONAL-CANCER-INSTITUTE-OF-CANADA RANDOMIZED TRIAL IN NONSMALL-CELL LUNG-CANCER [J].
JAAKKIMAINEN, L ;
GOODWIN, PJ ;
PATER, J ;
WARDE, P ;
MURRAY, N ;
RAPP, E .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) :1301-1309
[10]  
MCDURRAY SD, 1997, AM J KIDNEY DIS, V30, P542